A Phase 1 interventional study of Ivermectin and Placebo in Covid19, sponsored by MedinCell S.A. Completed at 1 site in United Kingdom. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-12-27.
Sponsored by MedinCell S.A · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 55 studies testing ivermectin in COVID-19 — 2 open to participants now, 2 under way, 1 of them phase 3. Ivermectin · COVID-19.
Among the 55 studies testing ivermectin in COVID-19, this one is the 52nd largest by enrollment, is one of 31 that started in 2020, is one of 3 in phase 1, and was the 22nd registered.
7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.
Browse COVID-19 studies →2 of the 55 studies testing ivermectin in COVID-19 are open now, in 12 countries. Recruiting first, the newest first:
University of Oxford · Sites in Brazil, Laos, Nepal and 2 more countries
Ages 18–60
UMC Utrecht · Sites in United States, Australia, Belgium and 26 more countries
Ages 28 days+
By country, each count listing its studies:
Ivermectin: first FDA approval 1996 (STROMECTOL). What it is approved for, and how studies give it, is on its page →
Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.
This study: 18 Years to 45 Years · male · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
55 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 26 · Phase 3 26 · Phase 4 5
First in 2016; this study’s year is marked. 31 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 24 is below the median of 102 across 4,367 interventional studies indexed under COVID-19.
Median enrollment 180 across the 55 interventional studies. Of the 32 that completed or were terminated, 11 (34%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 55 have an industry lead sponsor. The 10 most frequent:
MedinCell S.A is the lead sponsor of 2 studies on the registry; none are open to participants now.
MedinCell S.A has 2 studies filed under COVID-19 — fewer than ten, so there is no comparison to draw.
1 of the studies testing ivermectin in COVID-19 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05041907University of OxfordFinding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV) | 2027-01 |
Add it to your calendar (.ics) → With an account.
Among the 55 studies testing ivermectin in COVID-19, from their registry updates:
This tab as a report to print or save as PDF → With an account.
An early stage trial to check how safe and tolerable, as well as how the body handles continuous daily use of Active IMP over 28 days in healthy volunteers.
Detailed information restricted because this is a Phase 1 clinical trial.
Important Inclusion Criteria:
Important Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ivermectin loading dose of 200 mcg/kg followed by daily doses of 50mcg/kg from D2 to D28
Drug: Ivermectin
Ivermectin loading dose of 200 mcg/kg followed by daily doses of 75mcg/kg from D2 to D28
Drug: Ivermectin
Ivermectin loading dose of 200 mcg/kg followed by daily doses of 100mcg/kg from D2 to D28
Drug: Ivermectin
Placebo using tablets identical to the Active IMP
Drug: Placebo
Ivermectin: Investigation of the safety, tolerability and the pharmacokinetic profile of the active IMP in an exploratory study
Matching Placebo to the Active IMP.
Pharmacokinetic Concentrations - (Maximum Plasma Concentration [Cmax])
Maximum plasma concentration (Cmax)
Time frame: D1, D2 and D28
Pharmacokinetic Concentrations - (Time to Reach Cmax [Tmax])
Time to reach Cmax (Tmax)
Time frame: D1, D2 and D28
Pharmacokinetic Concentrations - (Area Under the Plasma Concentration-time Curve From Zero to 24 Hours [AUC0-24hr])
area under the plasma concentration-time curve from zero to 24 hours (AUC0-24hr) concentration-time curve from zero to 24 hours (AUC0-24hr)
Time frame: D1, D2 and D28
Pharmacokinetic Concentrations - (Apparent Terminal Half-Life [T1/2])
apparent terminal half-life (t1/2)
Time frame: D28
Safety and Tolerability - Treatment Emergent Adverse Events (TEAEs)
Clinical safety data from adverse event (AE) reporting
Time frame: From Screening (Day -28) to Follow up visit (Day +42) plus 7 additional days.
| Milestone | 50mcg/kg (Oral) | 75mcg/kg (Oral) | 100mcg/kg (Oral) | Matching Placebo (Oral) |
|---|---|---|---|---|
| Started | 6 | 6 | 6 | 6 |
| Completed | 6 | 6 | 5 | 6 |
| Not completed | 0 | 0 | 1 | 0 |
Maximum plasma concentration (Cmax)
| ng/mL | 50mcg/kg (Oral) | 75mcg/kg (Oral) | 100mcg/kg (Oral) |
|---|---|---|---|
| Day 1 after loading dose of 200mcg/kg (oral) for all active treatment groups | 57.2 ± 28.9 | 41.7 ± 73.5 | 46.5 ± 53.6 |
| Day 2 (first day on respective dose of active treatment) | 22.3 ± 32.5 | 24.4 ± 42.5 | 33.2 ± 62.6 |
| Day 28 (last day of active treatment) | 23.3 ± 52.8 | 31.9 ± 27.6 | 44.4 ± 68.8 |
Time to reach Cmax (Tmax)
| hr | 50mcg/kg (Oral) | 75mcg/kg (Oral) | 100mcg/kg (Oral) |
|---|---|---|---|
| Day 1 after loading dose of 200mcg/kg (oral) for all active treatment groups | 2.53 ± 36.8 | 3.03 ± 50.6 | 4.8 ± 47.2 |
| Day 2 (first day on respective dose of active treatment) | 3.82 ± 36.7 | 2.85 ± 38.8 | 3.23 ± 34.5 |
| Day 28 (last day of active treatment) | 2.83 ± 39.2 | 3.03 ± 50.7 | 3.03 ± 39.4 |
area under the plasma concentration-time curve from zero to 24 hours (AUC0-24hr) concentration-time curve from zero to 24 hours (AUC0-24hr)
| ng*h/mL | 50mcg/kg (Oral) | 75mcg/kg (Oral) | 100mcg/kg (Oral) |
|---|---|---|---|
| Day 1 after loading dose of 200mcg/kg (oral) for all active treatment groups | 568 ± 33.6 | 449 ± 62.0 | 523 ± 60.5 |
| Day 2 (first day on respective dose of active treatment) | 906 ± 31.4 | 779 ± 53.1 | 941 ± 59.0 |
| Day 28 (last day of active treatment) | 1.06 ± 36.6 | 1.5 ± 47.5 | 1.75 ± 20.6 |
apparent terminal half-life (t1/2)
| hr | 50mcg/kg (Oral) | 75mcg/kg (Oral) | 100mcg/kg (Oral) |
|---|---|---|---|
| Pharmacokinetic Concentrations - (Apparent Terminal Half-Life [T1/2]) | 102 ± 60.1 | 99.2 ± 47.3 | 127 ± 47.2 |
Clinical safety data from adverse event (AE) reporting
| TEAE | 50mcg/kg (Oral) | 75mcg/kg (Oral) | 100mcg/kg (Oral) | Matching Placebo (Oral) |
|---|---|---|---|---|
| Any TEAE | 24 | 5 | 2 | 21 |
| Any serious TEAE | 0 | 0 | 0 | 0 |
| Any TEAE leading to discontinuation - due to Study Medication-related TEAE | 0 | 0 | 0 | 0 |
| Any TEAE leading to discontinuation - other reason | 0 | 0 | 1 | 0 |
| TEAE - mild severity | 24 | 5 | 2 | 20 |
| TEAE - moderate severity | 0 | 0 | 0 | 1 |
| Causality (All TEAEs) - Not related | 21 | 3 | 2 | 20 |
| Causality (All TEAEs) - Related (possibly and probably) | 3 | 2 | 0 | 1 |
Collected over From Screening (Day -28) to Follow up visit (Day +42) plus 7 additional days. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 50mcg/kg (Oral) | 0/6 (0%) | 0/6 (0%) | 6/6 (100%) |
| 75mcg/kg (Oral) | 0/6 (0%) | 0/6 (0%) | 3/6 (50%) |
| 100mcg/kg (Oral) | 0/6 (0%) | 0/6 (0%) | 2/6 (33.3%) |
| Matching Placebo (Oral) | 0/6 (0%) | 0/6 (0%) | 6/6 (100%) |
| Ivermectin Overall | 0/18 (0%) | 0/18 (0%) | 11/18 (61.1%) |
| Total (Ivermectin Overall and Placebo) | 0/24 (0%) | 0/24 (0%) | 17/24 (70.8%) |
| Event | 50mcg/kg (Oral) | 75mcg/kg (Oral) | 100mcg/kg (Oral) | Matching Placebo (Oral) | Ivermectin Overall | Total (Ivermectin Overall and Placebo) |
|---|---|---|---|---|---|---|
| NauseaGastrointestinal disorders | 3/6 | 0/6 | 0/6 | 1/6 | 3/18 | 4/24 |
| HeadacheNervous system disorders | 3/6 | 0/6 | 1/6 | 1/6 | 4/18 | 5/24 |
| LethargyNervous system disorders | 1/6 | 0/6 | 0/6 | 2/6 | 1/18 | 3/24 |
| SomnolenceNervous system disorders | 2/6 | 0/6 | 0/6 | 0/6 | 2/18 | 2/24 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 0/6 | 0/6 | 0/6 | 2/6 | 0/18 | 2/24 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 2/6 | 0/6 | 0/6 | 0/6 | 2/18 | 2/24 |
| PalpitationsCardiac disorders | 1/6 | 1/6 | 0/6 | 0/6 | 2/18 | 2/24 |
| DiarrhoeaGastrointestinal disorders | 1/6 | 0/6 | 0/6 | 0/6 | 1/18 | 1/24 |
| ToothacheGastrointestinal disorders | 0/6 | 0/6 | 0/6 | 1/6 | 0/18 | 1/24 |
| Chest discomfortGeneral disorders | 0/6 | 0/6 | 0/6 | 1/6 | 0/18 | 1/24 |
| Age, Continuous(years) | 50mcg/kg (Oral) | 75mcg/kg (Oral) | 100mcg/kg (Oral) | Matching Placebo (Oral) | Total |
|---|---|---|---|---|---|
| Mean | 35.2 (25 to 45) | 29.3 (21 to 43) | 30.3 (21 to 43) | 28.2 (23 to 35) | 30.8 (21 to 45) |
| Sex: Female, Male(Participants) | 50mcg/kg (Oral) | 75mcg/kg (Oral) | 100mcg/kg (Oral) | Matching Placebo (Oral) | Total |
|---|---|---|---|---|---|
| Female | 0 | 0 | 0 | 0 | 0 |
| Male | 6 | 6 | 6 | 6 | 24 |
| Race and Ethnicity Not Collected(Participants) | 50mcg/kg (Oral) | 75mcg/kg (Oral) | 100mcg/kg (Oral) | Matching Placebo (Oral) | Total |
|---|---|---|---|---|---|
| Count of participants | — | — | — | — | 0 |
| Region of Enrollment(participants) | 50mcg/kg (Oral) | 75mcg/kg (Oral) | 100mcg/kg (Oral) | Matching Placebo (Oral) | Total |
|---|---|---|---|---|---|
| United Kingdom | 6 | 6 | 6 | 6 | 24 |
| Body Mass Index(kg/m^2) | 50mcg/kg (Oral) | 75mcg/kg (Oral) | 100mcg/kg (Oral) | Matching Placebo (Oral) | Total |
|---|---|---|---|---|---|
| Mean | 24.95 (19.43 to 30.85) | 25.79 (21.73 to 29.24) | 25.84 (20.04 to 31.65) | 25.57 (23.57 to 29.10) | 25.54 (19.43 to 31.65) |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Sep 2020 to primary completion in Mar 2021, 5 months.
Results were first posted in Dec 2021, 9 months after primary completion.
Of 233 industry-sponsored phase 1 interventional studies under COVID-19, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 12. This study's 5 months is below that.
Counting every sponsor, half of 384 studies reached it within 7 months; a quarter within 3 and three quarters within 15.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ivermectin
MedinCell S.A